Dianthus Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $6.2M | $2.8M | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $145.6M | $83.1M | $32.8M | $59.2M | $41.3M | $27.9M | $5.8M |
| SG&A Expense | $34.3M | $25.0M | $18.2M | $23.8M | $18.6M | $7.8M | $3.5M |
| Operating Income | $-177.9M | $-101.9M | $-48.2M | $-83.0M | $-60.0M | $-35.7M | $-9.3M |
| Operating Margin | -8,739.3% | -1,633.7% | -1,704.7% | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | $163.0K |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-162.3M | $-85.0M | $-43.6M | $-76.8M | $-57.5M | $-35.5M | $-9.4M |
| Net Margin | -7,973.3% | -1,362.8% | -1,541.2% | — | — | — | — |
| EPS (Basic) | $-4.20 | $-2.55 | $-1.41 | $-0.06 | $-0.09 | $-0.53 | $-1.81 |
| EPS (Diluted) | $-4.20 | $-2.55 | $-1.41 | $-0.06 | $-0.09 | $-0.53 | $-1.81 |
| Shares Outstanding (Basic) | 38.6M | 33.3M | 30.9M | 1.41B | 1.20B | 84.6M | — |
| Shares Outstanding (Diluted) | 38.6M | 33.3M | 30.9M | 1.41B | 1.20B | 84.6M | — |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | — | — | — | — |